BioNTech (BNTX)

• Market cap: $22.9B
• 1 day: -0.88%
• 5 days: -3.88%
• 1 month: -20.52%
• 3 months: -15.97%
• 6 months: -15.63%
• Year to date: -17.28%
• 1 year: 3.69%
• 5 years: 85.89%
• 10 years: 569.80%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

39% more call options, than puts

Call options by funds: $373M | Put options by funds: $269M

29% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 49

10% more capital invested

Capital invested by funds: $5.25B [Q3] → $5.78B (+$536M) [Q4]

2.71% more ownership

Funds ownership: 18.63% [Q3] → 21.34% (+2.71%) [Q4]

1% more funds holding

Funds holding: 294 [Q3] → 298 (+4) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 85

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $139 46% upside
• Avg. target: $154 62% upside
• High target: $172 80% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Geoff Meacham 62% 1-year accuracy 21 / 34 met price target	52% upside $145	Buy Initiated	13 Mar 2025
Morgan Stanley Terence Flynn 37% 1-year accuracy 7 / 19 met price target	46% upside $139	Overweight Maintained	11 Mar 2025
Canaccord Genuity John Newman 30% 1-year accuracy 8 / 27 met price target	80% upside $171	Buy Maintained	11 Mar 2025
BMO Capital Etzer Darout 21% 1-year accuracy 7 / 34 met price target	50% upside $143	Outperform Maintained	11 Mar 2025
Truist Securities Asthika Goonewardene 24% 1-year accuracy 6 / 25 met price target	80% upside $172	Buy Initiated	10 Jan 2025